These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9252130)

  • 1. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants.
    von Weizsäcker F; Wieland S; Köck J; Offensperger WB; Offensperger S; Moradpour D; Blum HE
    Hepatology; 1997 Aug; 26(2):251-5. PubMed ID: 9252130
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense strategies in degenerative joint diseases: sense or nonsense?
    Huber LC; Distler O; Gay RE; Gay S
    Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Attempts to use gene therapy for reducing connective tissue disorders--osteogenesis imperfecta].
    Gajko-Galicka A
    Postepy Biochem; 2003; 49(1):18-25. PubMed ID: 14518394
    [No Abstract]   [Full Text] [Related]  

  • 4. Antisense inhibition: oligonucleotides, ribozymes, and siRNAs.
    Zhang YC; Taylor MM; Samson WK; Phillips MI
    Methods Mol Med; 2005; 106():11-34. PubMed ID: 15375310
    [No Abstract]   [Full Text] [Related]  

  • 5. [Gene therapy approaches in chronic viral hepatitis].
    Souvignet C; Zarski JP
    Therapie; 2000; 55(3):333-41. PubMed ID: 10967709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?
    Akhtar S; Rossi JJ
    J Antimicrob Chemother; 1996 Aug; 38(2):159-65. PubMed ID: 8877530
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prospects of antisense therapy technologies].
    Skoblov MIu
    Mol Biol (Mosk); 2009; 43(6):984-98. PubMed ID: 20088374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic antisense and ribozymes.
    Rossi JJ
    Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozyme therapeutics.
    Persidis A
    Nat Biotechnol; 1997 Sep; 15(9):921-2. PubMed ID: 9306412
    [No Abstract]   [Full Text] [Related]  

  • 10. Translating genomics information into therapeutics: a key role for oligonucleotides.
    Christoffersen RE
    Nat Biotechnol; 1997 Jun; 15(6):483-4. PubMed ID: 9181554
    [No Abstract]   [Full Text] [Related]  

  • 11. Nucleic-acid therapeutics: basic principles and recent applications.
    Opalinska JB; Gewirtz AM
    Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense inhibitors, ribozymes, and siRNAs.
    Thompson AJ; Patel K
    Clin Liver Dis; 2009 Aug; 13(3):375-90. PubMed ID: 19628155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repression of hepatitis B virus X gene expression by hammerhead ribozymes.
    Kim YK; Junn E; Park I; Lee Y; Kang C; Ahn JK
    Biochem Biophys Res Commun; 1999 Apr; 257(3):759-65. PubMed ID: 10208856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes.
    Nash KL; Alexander GJ; Lever AM
    J Viral Hepat; 2005 Jul; 12(4):346-56. PubMed ID: 15985004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.
    Alvarez-Salas LM; Benítez-Hess ML; DiPaolo JA
    Antivir Ther; 2003 Aug; 8(4):265-78. PubMed ID: 14518695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance.
    Funato T
    Methods Mol Med; 2005; 106():215-33. PubMed ID: 15375319
    [No Abstract]   [Full Text] [Related]  

  • 19. Antisense technologies have a future fighting neurodegenerative diseases.
    Seidman S; Eckstein F; Grifman M; Soreq H
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes.
    Lavrovsky Y; Chen S; Roy AK
    Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.